ArticleCureus2025
A New WHO Entity of SMARCB1/INI1-Deficient Undifferentiated Thoracic Tumors: Rare, Aggressive, and Overlooked.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SMARCB1/INI1-deficient undifferentiated tumors of the thorax represent a very rare and highly aggressive group of malignancies characterized by rapid progression and considerable diagnostic challenges. Their clinical and radiological features are often nonspecific, while their histological appearance - frequently rhabdoid or undifferentiated - overlaps with several other high-grade thoracic neoplasms. Because these tumors generally lack lineage-defining immunohistochemical markers, diagnosis requires an integrated approach combining morphological assessment, broad immunohistochemical profiling, and confirmation of complete SMARCB1/INI1 loss. In this report, we describe a rare mediastinal case that illustrates the stepwise diagnostic process required to identify this entity. Key aspects of the differential diagnosis are discussed, along with relevant therapeutic implications. Early recognition of such tumors is crucial, as accurate diagnosis can significantly influence treatment strategies and facilitate enrollment in emerging clinical trials targeting SWI/SNF-deficient cancers. Recognition of this recently highlighted yet still unclassified entity within the 2021 WHO classification of thoracic tumors is essential, since timely and precise diagnosis - as demonstrated in our case - directly impacts therapeutic decision-making and enables access to novel targeted therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.